Business

MARKET MOVERS

Dendreon expects slowdown in sales

istockphoto.com

Dendreon makes Provenge, which is designed to induce an immune response against prostate cancer.

Advertisement

Dendreon Corp. expects first-quarter sales to be slower than in the fourth quarter, when sales of its prostate cancer treatment Provenge were $77 million. The Seattle drug maker said first-quarter revenue growth for the drug would be in the low single digits. Fourth-quarter net income was $38.1 million, or 26 cents a share. Profit excluding some items was 45 cents a share. Analysts expected 60 cents.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com